破发股东亚药业去年转亏 2020年上市2募资共15.74亿

Core Viewpoint - Dongya Pharmaceutical (605177.SH) reported a significant decline in financial performance for the year 2024, with a notable drop in both revenue and net profit compared to the previous year [1][2]. Financial Performance Summary - The company achieved an operating revenue of 1.198 billion yuan in 2024, a decrease of 11.66% year-on-year [2][3]. - The net profit attributable to shareholders was -100.66 million yuan, representing a decrease of 183.02% compared to the previous year [2][3]. - The net profit after excluding non-recurring gains and losses was -98.41 million yuan, down 191.03% year-on-year [2][3]. - The net cash flow from operating activities was -157 million yuan [1]. Quarterly Performance Summary - In the first quarter of 2025, the company reported an operating revenue of 191 million yuan, a decrease of 45.85% year-on-year [3]. - The net profit attributable to shareholders for Q1 2025 was -6.92 million yuan, down 128.78% compared to the same period last year [3]. - The net profit after excluding non-recurring gains and losses for Q1 2025 was -10.51 million yuan, a decrease of 151.56% year-on-year [3]. - The net cash flow from operating activities for Q1 2025 was -134.53 million yuan [3]. Fundraising and Financial Activities - Dongya Pharmaceutical raised a total of 884 million yuan through its IPO, with a net amount of 782 million yuan after deducting issuance costs [4]. - The funds were allocated for projects including the production of key intermediates for cephalosporin antibiotics and the construction of a research and development center [4]. - The company issued 6.9 million convertible bonds with a total fundraising amount of 69 million yuan, netting 68.02 million yuan after expenses [5].